Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Sees Significant Growth in Short Interest

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the recipient of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 6,900 shares, an increase of 146.4% from the November 15th total of 2,800 shares. Based on an average daily trading volume, of 6,100 shares, the short-interest ratio is presently 1.1 days.

Clinuvel Pharmaceuticals Price Performance

CLVLY stock traded up $0.18 during mid-day trading on Wednesday, reaching $8.30. 5,823 shares of the stock traded hands, compared to its average volume of 2,847. Clinuvel Pharmaceuticals has a 52-week low of $8.00 and a 52-week high of $11.71. The stock’s fifty day moving average is $9.07 and its 200-day moving average is $9.56.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).